Having trouble accessing articles? Reset your cache.

Durata, Synergy planning follow-ons

Infectious disease company Durata Therapeutics Inc. (NASDAQ:DRTX) amended and gastrointestinal company Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) proposed follow-ons after market

Read the full 195 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE